company background image
HOLX logo

Hologic NasdaqGS:HOLX Stock Report

Last Price

US$71.41

Market Cap

US$16.2b

7D

0.3%

1Y

-4.1%

Updated

29 Jan, 2025

Data

Company Financials +

HOLX Stock Overview

Engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. More details

HOLX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

My Notes

Capture your thoughts, links and company narrative

Hologic, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hologic
Historical stock prices
Current Share PriceUS$71.41
52 Week HighUS$84.67
52 Week LowUS$68.61
Beta0.98
1 Month Change-1.19%
3 Month Change-11.70%
1 Year Change-4.07%
3 Year Change-1.04%
5 Year Change31.46%
Change since IPO2,887.09%

Recent News & Updates

Hologic: Reasonably, But Not Compellingly Valued

Jan 17

Here's What To Make Of Hologic's (NASDAQ:HOLX) Decelerating Rates Of Return

Jan 13
Here's What To Make Of Hologic's (NASDAQ:HOLX) Decelerating Rates Of Return

Recent updates

Hologic: Reasonably, But Not Compellingly Valued

Jan 17

Here's What To Make Of Hologic's (NASDAQ:HOLX) Decelerating Rates Of Return

Jan 13
Here's What To Make Of Hologic's (NASDAQ:HOLX) Decelerating Rates Of Return

Earnings Not Telling The Story For Hologic, Inc. (NASDAQ:HOLX)

Dec 22
Earnings Not Telling The Story For Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 60% Above Its Share Price

Dec 04
Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 60% Above Its Share Price

When Should You Buy Hologic, Inc. (NASDAQ:HOLX)?

Nov 02
When Should You Buy Hologic, Inc. (NASDAQ:HOLX)?

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Oct 28

Hologic (NASDAQ:HOLX) Seems To Use Debt Rather Sparingly

Oct 17
Hologic (NASDAQ:HOLX) Seems To Use Debt Rather Sparingly

Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Sep 16
Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar

Sep 01
Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Aug 27

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Jul 21
Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Jun 20
These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

May 22
Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

May 13

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Apr 19
Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Apr 05
Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Mar 20
Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Feb 22
Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

Feb 11

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Feb 09
We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Feb 06
Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Shareholder Returns

HOLXUS Medical EquipmentUS Market
7D0.3%1.3%-0.8%
1Y-4.1%15.0%25.2%

Return vs Industry: HOLX underperformed the US Medical Equipment industry which returned 16.6% over the past year.

Return vs Market: HOLX underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is HOLX's price volatile compared to industry and market?
HOLX volatility
HOLX Average Weekly Movement3.1%
Medical Equipment Industry Average Movement8.8%
Market Average Movement6.5%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: HOLX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: HOLX's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19857,063Steve MacMillanwww.hologic.com

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Hologic, Inc. Fundamentals Summary

How do Hologic's earnings and revenue compare to its market cap?
HOLX fundamental statistics
Market capUS$16.20b
Earnings (TTM)US$789.50m
Revenue (TTM)US$4.03b

20.4x

P/E Ratio

4.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HOLX income statement (TTM)
RevenueUS$4.03b
Cost of RevenueUS$1.58b
Gross ProfitUS$2.45b
Other ExpensesUS$1.66b
EarningsUS$789.50m

Last Reported Earnings

Sep 28, 2024

Next Earnings Date

Feb 05, 2025

Earnings per share (EPS)3.50
Gross Margin60.73%
Net Profit Margin19.59%
Debt/Equity Ratio49.4%

How did HOLX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 07:30
End of Day Share Price 2025/01/29 00:00
Earnings2024/09/28
Annual Earnings2024/09/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hologic, Inc. is covered by 51 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays